Dimethyl fumarate (DMF; Tecfidera) is a chemical approved by the US Food and Drug Administration for treating multiple sclerosis.[7] Previous studies have shown that DMF can promote the polarization of macrophages to the M2 subtype and inhibit pyroptosis by targeting Gasdermin D (GSDMD).[8] Therefore, the local application of the DMF slow‐release system could be an effective complement to NGCs for regulating the IME. This evidence concerns the gene GSDMD and multiple sclerosis.